Flydubai Co-Pilot Tried to Crash Israel-Bound Jet, Netanyahu Says 
Sanofi, Regeneron Expand Drug Partnership in $8 Billion Deal 
WordPress Malware Uses Ethereum to Evade Removal 
Citi Raises Bitcoin Target to $113,000 as Crypto Outlook Improves 
Goldman Sachs Names CATL, Zenergy Top China Battery Picks 
AAVE, PUMP, WLD and SKY Rally as Crypto Market Slips 
Zcash Awards $8 Million in Grants After Orchard Bug Crisis 
Coinbase, Circle Stocks Slide as Bank Group Sues OCC Over Crypto Charters 
Volvo Cars Drops Full-Year Outlook as China, US Sales Weaken 
Robinhood Stock Nears $114 as Jobs Data Boosts Risk Appetite 
Evernorth Set for Nasdaq Debut With 473 Million XRP Treasury 
Circle Urges EU to Revise MiCA Stablecoin Rules 
XRP Ledger Hits 10 Million AI Payments as Bitcoin Retreats 
Italgas to Buy 22.5% Stake in Portugal’s Floene for €120 Million 
SoftBank Shares Fall After $10 Billion OpenAI Investment 
Bank of America Sees EUR/USD at 1.15 by Year-End 
Add as a preferred source on Google
PARSIPPANY, N.J., May 10, 2017 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the Bank of America Merrill Lynch 2017 Healthcare Conference at 8:00 AM PT on Wednesday, May 17, 2017 in Las Vegas.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Susan Mesco (973) 451-4030 [email protected]
